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Objectives We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary
drug-eluting stents (DES).
Background The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet re-
activity and to improve clinical outcomes after percutaneous coronary intervention in previous studies.
Methods In a randomized multicenter trial, we enrolled 960 patients who received DES. They were randomized to receive
either dual antiplatelet therapy (DAT) (aspirin and clopidogrel) or triple antiplatelet therapy (TAT) (aspirin, clopi-
dogrel, and cilostazol) for 6 months. Primary end point was the composite of cardiac death, nonfatal myocardial
infarction, ischemic stroke, or target lesion revascularization (TLR). Secondary end points were P2Y12 reaction
unit (PRU) measured with the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) at discharge and at 6
months after the index procedure. All-cause death, stent thrombosis, and each component of the primary end
point at 6 months were other secondary end points. Analysis was done on an intention-to-treat basis.
Results At 6 months’ follow-up, there was no difference in the primary end point between the 2 groups (8.5% in TAT vs. 9.2% in
DAT, p 0.74). In secondary end point analysis, the TAT group achieved lower PRU levels than the DAT group both at dis-
charge (206.6 90.3 PRU vs. 232.2 80.3 PRU, p 0.001) and at 6 months (210.7 87.9 PRU vs. 255.7 73.7
PRU, p 0.001). In the Cox proportional hazards analysis, lesion length (28mm, hazard ratio [HR]: 2.10, 95% confi-
dence interval [CI]: 1.25 to 3.52), and PRU level at discharge (every increase in tertile, HR: 1.61, 95% CI: 1.16 to 2.25) were
predictors of the primary end point, but not the use of cilostazol (HR: 0.90, 95% CI: 0.54 to 1.52).
Conclusions Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not
show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The
Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828) (J Am Coll
Cardiol 2011;57:280–9) © 2011 by the American College of Cardiology Foundation
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January 18, 2011:280–9 Cilostazol and Ischemic Events After PCIrug-eluting stents (DES) reduce the rate of restenosis and
ave expanded the application of percutaneous coronary inter-
entions (PCI). However, restenosis still exists (1,2), and there
re concerns about long-term thrombotic complications after
ES (3–5).
See page 290
DES implantation is typically followed by aspirin plus
lopidogrel therapy (DAT). However, a substantial number
f patients, 15% to 30%, have high residual platelet reac-
ivity on DAT, and there have been reports describing an
ssociation between high post-treatment platelet reactivity
PPR) and atherothrombotic cardiovascular complications
fter PCI (6–8). Among various assays assessing PPR, the
esults of VerifyNow P2Y12 (Accumetrics, San Diego,
alifornia) have shown good predictability of atherothrom-
otic outcomes (8–10). However, these studies are based on
ata for Caucasians. There are few reports about the efficacy
f the VerifyNow P2Y12 system in predicting clinical
utcomes in Asians.
Cilostazol is a selective phosphodiesterase-3 inhibitor
hat is commonly used as a vasodilator with antiplatelet
ctivity in patients with peripheral arterial disease (11). In
ddition, it has been reported to have anti-inflammatory
nd antiapoptotic effects (12,13), and has reduced restenosis
n studies with coronary stents (14–17). Adjunctive cilosta-
ol treatment on top of the standard DAT (triple antiplate-
et therapy [TAT]), in patients with type 2 diabetes melli-
us, enhances inhibition of platelet P2Y12 signaling, and
ilostazol intensifies platelet inhibition in patients who
howed high PPR despite conventional DAT (18,19).
egistry data have shown that TAT reduced stent throm-
osis, nonfatal myocardial infarction (MI), and cardiac
eath compared with DAT (20,21).
Following these favorable results, cilostazol has been
uggested as a powerful candidate of adjunctive therapy that
an overcome limitations of DES, with respect to both
hrombosis and restenosis. However, there have been no
arge-scale randomized trials to verify superiority of TAT to
AT in the inhibition of platelet reactivity and in reducing
dverse clinical outcomes in patients who underwent DES
mplantation.
The aim of the present clinical trial (CILON-T [The
fficacy of CILostazol ON Ischemic Complications After
ES Implantation]) was to assess the safety and the efficacy
f TAT versus DAT in reducing adverse cardiovascular
utcomes including thrombosis and restenosis in the real-
orld all-comer patients with DES implantation. Another
im is to verify the superiority of TAT to DAT in the
nhibition of platelet reactivity.
ethods
atients. The CILON-T trial (22) was a prospective,
pen-label randomized trial at 5 centers in South Korea: the ueoul National University Hos-
ital, Seoul National University
undang Hospital, Korea Guro
ospital, Konyang University
ospital, and Chungbuk Na-
ional University Hospital. Pa-
ients were enrolled between
eptember 2006 and June 2009.
en and women were eligible if
hey were 18 to 80 years of age,
ad angina pectoris or a positive
tress test, and had native coro-
ary artery lesions for which
ES implantation was feasible.
easons for exclusion were: he-
atic dysfunction; renal dysfunc-
ion (serum creatinine 2.0
g/dl or on dialysis); left ventric-
lar ejection fraction 30% or
ew York Heart Association
unctional class III or IV; uncor-
ected hematological disease;
ontraindication to or history of
llergy to aspirin, clopidogrel, or
ilostazol; or expected survival
2 years because of other medi-
al conditions. Patients already
aking warfarin or antiplatelet agents except aspirin or
lopidogrel were also excluded. All patients gave written
nformed consent, and the institutional review boards at 5
enters approved this study.
rocedures. All patients were given aspirin and clopidogrel
efore coronary intervention. Loading doses of aspirin (300
g) and clopidogrel (300 to 600 mg) were given to patients
ho had not taken aspirin or clopidogrel before. Aspirin
100 mg daily) and clopidogrel (75 mg daily) were given for
t least 6 months. Patients were randomly assigned to DAT
r TAT. Stratification was performed according to the
articipating center and the type of statin (CYP3A4 me-
abolized vs. non-CYP3A4 metabolized) in order to rule out
ny potential statin–clopidogrel drug interaction. This was
n open-label study with blinded evaluation, and a placebo
as not used. The TAT group received a loading dose of
ilostazol 200 mg, and then 100 mg twice daily for 6 months
n top of conventional DAT. Coronary stenting was per-
ormed according to standard PCI technique. The decision
f pre-dilation or direct stenting was made by the operator,
s was the use of glycoprotein IIb/IIIa inhibitor.
latelet function test. The VerifyNow assay is a point-
f-care assay using whole blood and was utilized accord-
ng to the instructions of the manufacturer (18,23). The
erifyNow P2Y12 assay reports the results as P2Y12
eaction units (PRU). This assay mimics turbidometric
ggregation and utilizes disposable cartridges containing
0 M ADP and 22 nM PGE1. Aggregation testing
Abbreviations
and Acronyms
CI  confidence interval
DAT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
NPV  negative predictive
value
PCI  percutaneous
coronary intervention
PPR  post-treatment
platelet reactivity
PPV  positive predictive
value
PRU  P2Y12 reaction unit
ROC  receiver-operating
characteristic
TAT  triple antiplatelet
therapy
TIMI  Thombolysis In
Myocardial Infarction
TLR  target lesion
revascularizationsing ADP as a sole agonist activates P2Y1 and P2Y12
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Cilostazol and Ischemic Events After PCI January 18, 2011:280–9urinergic signaling; adding PGE1 increases the specific-
ty of the test for P2Y12 signaling (18,24). In a separate
hannel of the cartridge in which iso-TRAP is used as an
gonist, a baseline value for platelet function is obtained,
nabling assessment of platelet inhibition (% inhibition)
ithout having to wean the patient off antiplatelet
reatment. We performed the VerifyNow P2Y12 assay at
ischarge and at 6 months after the index procedure.
tudy end points and clinical follow-up. The primary end
oint of the CILON-T trial was the composite of major
dverse cardiovascular events, cardiac death, nonfatal MI,
linically driven target lesion revascularization (TLR), and
schemic stroke at 6 months.
Secondary end points were PRU levels measured at
ischarge and at 6 months after DES implantation. Other
econdary end points were all-cause death, stent thrombosis,
nd each component of the primary end point at 6 months.
Safety assessments included bleeding complications ac-
ording to Thombolysis In Myocardial Infarction (TIMI)
riteria (25), heart rate, and the incidence of drug discon-
inuation during the treatment period.
The cause of death was regarded as cardiovascular unless
here was documented evidence of a clear noncardiovascular
ause. MI was defined as a creatinine kinase myocardial
and 3 times upper limit of normal. Ischemic stroke was
efined as a new focal neurologic deficit of vascular origin
asting at least 24 h that was proven to be nonhemorrhagic
y either computed tomography or magnetic resonance
maging scanning. TLR was considered clinically driven
hen it was associated with typical symptoms on clinical
ssessment, typical signs on stress test, or 70% diameter
tenosis on angiographic follow-up. Stent thrombosis was
efined as any of the following: angiographic documenta-
ion of occlusion of the target lesion associated with an acute
schemic event, irrespective of the presence of angiographi-
ally visible thrombi, unexplained sudden death, and MI not
learly relevant to another coronary lesion.
Clinical follow-up was done at 1, 3, and 6 months and 1
ear, and all patients were recommended to have follow-up
oronary angiography at 6 months. The investigators followed
he patients, either by office visits or by telephone contacts as
ecessary. The compliance of the drugs and adverse events
ere assessed at every visit for clinical follow-up.
tatistical analysis. To test the hypothesis that TAT is
uperior to DAT in reducing the primary end point at 6
onths after the index procedure, the event rate was
ssumed to be 10% in the DAT group and 5% in the TAT
roup, respectively, based on previously published reports
15,16,26,27). Using a superiority design, it was estimated
hat a total of 960 patients would be needed to ensure a
ower of 80% to detect a 5% difference in the primary end
oint between the 2 groups using a 2-tailed test, with a
ampling ratio of DAT:TAT at 1:1, bilateral risk set at 5%,
nd the estimated dropout rate of 10%.
Analyses of the 2 groups were performed according to thentention-to-treat principle. The Kolmogorov-Smirnov test das used for normality test. Comparison of continuous
ariables was performed using Student t test or, in the case
f non-normal distribution, Mann-Whitney U test as ap-
ropriate. Categorical variables were presented as numbers
r percentages and were compared using chi-square or
ischer exact tests. Analysis of platelet function test was
erformed with repeated measures analysis of variance
ethod with the Bonferroni correction. Pre-specified sub-
roup analysis according to diabetes mellitus, age, sex, and
ngiographic variables (lesion length, reference vessel diam-
ter) was performed. Cox proportional hazards analysis was
sed to assess clinical and angiographic predictors of adverse
linical outcomes. A receiver-operating characteristic (ROC)
urve analysis was used to determine the ability of the
ost-treatment platelet reactivity to distinguish between
atients with and without atherothrombotic events after
CI. The best cutoff value was defined as the point with the
ighest sum of sensitivity and specificity. SPSS version 17.0
SPSS Inc., Chicago, Illinois) was used for all statistical
nalyses, and p  0.05 was considered statistically significant.
ole of funding source. Neither the Innovative Research
nstitute for Cell Therapy nor Clinical Research Center
or Ischemic Heart Disease, Ministry of Health & Welfare
ad involvement in study design, in collection, analysis, or
nterpretation of data, or in writing of the report. The
orresponding author had full access to all the data in the
tudy and had the final responsibility for the decision to
ubmit for publication.
esults
he clinical trial algorithm is shown in Figure 1. Among the
nitially randomized patients, 5 patients withdrew consent,
patients failed to implant DES for the target lesion, and
3 patients withdrew from the study by the duty physician’s
udgment for several reasons, which included high risk of
ignificant bleeding in the near future, and planned opera-
ion that needed antiplatelet agent modification or discon-
inuation. The total dropout rate was about 5% in each
roup (i.e., within the expected range) and did not differ
ignificantly between the groups.
Baseline clinical, angiographic, and procedural characteris-
ics of the 915 patients who entered the study are shown in
ables 1 and 2. No significant differences existed between the
groups. Profiles of medication at discharge were not different
etween the 2 groups except angiotensin-converting enzyme
ACE) inhibitor/angiotensin II receptor blocker (ARB), which
ere more frequently prescribed in the DAT than in the TAT
roup (45.2% vs. 37.0%, p  0.012) (Table 3).
PR in 2 groups. The VerifyNow P2Y12 assay was
erformed at 2 different time points: at discharge (n 
16, TAT: n  355, DAT: n  361) and 6 months (n 
08, TAT: n  299, DAT: n  309) after the index
rocedure. The duration of hospital stay after the procedure
as not different between the 2 groups (TAT: 2.09  1.37
ays vs. DAT: 1.99  1.14 days, p  0.33). The TAT
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January 18, 2011:280–9 Cilostazol and Ischemic Events After PCIFigure 1 Flow of Patients Through the Study
DAT  dual antiplatelet therapy; MI  myocardial infarction; PCI  percutaneous coronary intervention;
PRU  P2Y reaction unit; TAT  triple antiplatelet therapy; TLR  target lesion revascularization.12Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
TAT
(n  457)
DAT
(n  458) p Value
Age, yrs 64.8 (13) 64.0 (13) 0.79
Men 321 (68.6%) 326 (68.3%) 0.94
Hypertension 291 (64.5%) 305 (66.9%) 0.45
Diabetes mellitus 160 (35.5%) 147 (32.2%) 0.30
Dietary therapy alone 24 (5.3%) 17 (3.7%)
Oral hypoglycemic agent 103 (22.8%) 116 (25.4%)
Insulin 33 (7.3%) 14 (3.1%)
Current smoker 107 (23.7%) 122 (26.8%) 0.47
Previous percutaneous coronary intervention 29 (6.4%) 39 (8.6%) 0.23
Previous coronary artery bypass surgery 8 (1.8%) 13 (2.7%) 0.28
Clinical diagnosis 0.75
Stable angina 168 (41.3%) 153 (37.1%)
Unstable angina 174 (42.8%) 196 (47.6%)
Acute myocardial infarction 42 (10.3%) 42 (10.2%)
Silent ischemia 8 (1.9%) 5 (1.2%)
Systolic BP (mm Hg) 130 (116–141) 126 (115–140) 0.30
Diastolic BP (mm Hg) 79.5 (70–87) 78 (70–84) 0.27
Heart rate, min1 68 (60–76.5) 68 (61–76) 0.76
Total cholesterol, mg/dl 175.0 (149.5–201.0) 171.5 (146.0–205.0) 0.98
LDL cholesterol, mg/dl 102.1 (81.7–124.4) 104.0 (80.0–133.0) 0.60
Hematocrit, % 39.9 (36.9–42.7) 40.1 (37.5–42.8) 0.31
Creatinine, mg/dl 1.0 (0.9–1.2) 1.0 (0.9–1.1) 0.44Data are n (%) or median (interquartile range).
BP  blood pressure; DAT  dual antiplatelet therapy; LDL  low-density lipoprotein; TAT  triple antiplatelet therapy.
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Cilostazol and Ischemic Events After PCI January 18, 2011:280–9roup showed significantly lower PPR compared with the
AT group both at discharge (206.6 90.3 vs. 232.2 80.3,
 0.001) and at 6 months (210.7  87.9 vs. 255.7  73.7,
 0.001) after DES implantation (Fig. 2). The PRU level in
he DAT group significantly increased for 6 months between
time points, at discharge and 6 months after index procedure
p  0.001). In the TAT group, however, the PRU level did
ot change between the 2 time points (p  0.23). There was
significant difference in changes in PRU level between the 2
roups (p for interaction 0.046). The level of “% inhibition”
as also significantly different at each time point between the
rofiles of Medication at DischargeTable 3 Profiles of Medication at Discharge
TAT
(n  457)
DAT
(n  458) p Value
Aspirin 449 (98.2%) 451 (98.5%) 0.997
Statin 0.792
CYP3A4 metabolized 234 (51.2%) 230 (50.2%)
Non-CYP3A4 metabolized 223 (48.8%) 228 (49.8%)
Beta-blocker 239 (52.2%) 232 (50.7%) 0.691
ACE inhibitor or ARB 169 (37.0%) 207 (45.2%) 0.012
Calcium channel blocker 117 (26.0%) 123 (26.9%) 0.680
Nitrates 187 (40.9%) 193 (42.1%) 0.728
Proton pump inhibitor 12 (2.6%) 9 (2.0%) 0.488
alues are n (%).
Angiographic Characteristics and Procedural ReTable 2 Angiographic Characteristics and P
Lesion locations
Left anterior descending coronary artery
Left circumflex artery
Right coronary artery
Left main coronary artery
ACC/AHA lesion classification
A
B1
B2
C
Ostial lesions
Calcified lesions
Bifurcation lesion
Thrombus on angiography
Lesion length, mm
Reference vessel diameter, mm
Baseline minimum lumen diameter, mm
Post-procedural minimum lumen diameter, mm
Number of stents per lesion
Type of stents*
Paclitaxel-eluting stent (TAXUS)
Zotarolimus-eluting stent (Endeavor)
Multilesion intervention
Data are n (%) or median (interquartile range). *Other stents were si
eluting stent (Xience, Abbott Vascular, Santa Clara, California).
ACC/AHA  American College of Cardiology/American Heart AssocACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; other abbrevia-
ions as in Table 1.groups (at discharge after PCI, TAT: 34.9  24.7% vs.
AT: 24.5 21.6%, p 0.0001; at 6 months, TAT: 37.9
7.5% vs. DAT: 22.2  19.4%, p  0.0001).
Figure 2 PPR in DAT Versus TAT Measured by
the VerifyNow P2Y12 Assay
This figure shows P2Y12 reaction unit (PRU) level in both the dual antiplatelet
therapy (DAT) and triple antiplatelet therapy (TAT) groups at discharge and 6
months after the index procedure. The TAT group shows significantly lower
post-treatment platelet reactivity (PPR) than the DAT group in both stages. Data
represent mean and 95% confidence interval of the PRU of each group.
ural Results
TAT
 457)
DAT
(n  458) p Value
0.17
8.4%) 222 (49.3%)
0.2%) 107 (23.5%)
3.1%) 124 (27.6%)
.1%) 13 (2.9%)
0.63
.8%) 10 (2.3%)
9.7%) 126 (29.1%)
3.0%) 46 (10.6%)
4.5%) 251 (58.0%)
4.5%) 109 (23.8%) 0.80
4.1%) 128 (29.3%) 0.092
1.7%) 132 (28.8%) 0.56
.8%) 38 (8.7%) 0.64
3.4) 22.2 (13.9) 0.24
.64–3.28) 2.91 (2.61–3.24) 0.57
.42–1.07) 0.70 (0.45–1.13) 0.35
.95–2.58) 2.23 (1.87–2.58) 0.15
.0–1.0) 1.0 (1.0–1.0) 0.84
0.53
9.1%) 233 (51.4%)
6.7%) 196 (43.3%)
4.1%) 163 (35.6%) 0.64
-eluting stent (Cypher, Cordis, Miami Lakes, Florida) and everolimus-
other abbreviations as in Table 1.sultsroced
(n
220 (4
91 (2
105 (2
23 (5
12 (2
126 (2
55 (1
231 (5
112 (2
105 (2
145 (3
34 (7
21.1 (1
2.88 (2
0.66 (0
2.24 (1
1.0 (1
223 (4
212 (4
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January 18, 2011:280–9 Cilostazol and Ischemic Events After PCIlinical outcomes with DAT versus TAT. All (100%) of
he patients enrolled were followed up throughout the
uration of the study period. Angiographic follow-up was
one in 85.2% of the TAT and in 84.9% of the DAT groups
p  0.93), and there were no differences in the clinical and
ngiographic characteristics between patients with or with-
ut angiographic follow-up.
The clinical outcomes are summarized in Table 4. The
rimary end point, composite of cardiac death, MI, ischemic
troke, and TLR, was reached in 39 patients (8.5%) in the
AT group and 42 patients (9.2%) in the DAT group, which
id not show statistical significance (p  0.74) (Table 4). In
ddition, there were no differences between the 2 groups in the
econdary end points, such as death, MI, ischemic stroke,
LR, or any of these events combined. Subgroup analysis
ccording to clinical and angiographic characteristics demon-
Baseline characteristics
Diabetes 
Yes  
No 
Sex  
Male  
Female  
Lesion length  
≥ 28mm  
<28mm  
Reference vessel diameter   
<2.75mm 
≥2.75mm 
Age  
≥ 65 yr 
<65 yr 
0.1
TAT better 
Figure 3 HR Between DAT and TAT for Composite Cardiovascu
All data were presented on a logarithmic scale. HR  hazards ratio; CI  confiden
linical Outcomes During Follow-UpTable 4 Clinical Outcomes During Follow-Up
TAT
(n  457)
Primary end point
Cardiac death, nonfatal MI, ischemic stroke, and TLR 39 (8.5%)
Secondary end point
Death from any cause 4 (0.9%)
Cardiac death 0
Nonfatal MI 4 (0.9%)
Ischemic stroke 5 (1.1%)
TLR 30 (6.6%)
Stent thrombosis 3 (0.7%)
Death, nonfatal MI, ischemic stroke 13 (2.8%)
Cardiac death, nonfatal MI, ischemic stroke 9 (2.0%)
I  confidence interval; MI  myocardial infarction; OR  odds ratio; TLR  target lesion revasctrated no significant differences in clinical outcomes between
he 2 groups, except in female patients, in whom TAT showed
higher rate of adverse cardiac events than DAT (Fig. 3).
linical outcomes depending on PPR. To evaluate the
nfluence of PPR on clinical outcomes, we categorized all
he patients into 3 groups (184, 184 to 264, and 264
RU) depending on the PRU value at discharge. Patients
ended to have a different incidence of primary end point
ccording to tertile distribution of PRU levels during
ollow-up (p  0.077) (Fig. 4A). Atherothrombotic com-
lications, such as cardiac death, nonfatal MI, and ischemic
troke, were significantly different among the 3 tertile
roups of PPR (2.9% in the highest vs. 2.0% in the middle
s. 0% in the lowest, p 0.037) (Fig. 4B). The incidence of
LR had no association with tertile distribution of PRU
p  0.49) (Fig. 4C).
DAT better 
HR 95% CI
0.78  0.37-1.60  
1.02  0.57-1.83  
0.66  0.39-1.13  
3.41  1.12-10.4  
0.79  0.34-1.84  
0.70  0.38-1.31  
0.80  
0.85  
0.38-1.69  
0.45-1.60  
1.34  
0.64  
0.69-2.58  
0.32-1.29  
10
ents in Patients Grouped by Baseline Characteristics
rval; other abbreviations as in Figure 2.
DAT
(n  458) p Value OR 95% CI
42 (9.2%) 0.73 0.92 0.59–1.46
6 (1.3%) 0.75 0.67 0.19–2.37
3 (0.7%) 0.25 — —
3 (0.7%) 0.73 1.34 0.30–6.02
4 (0.9%) 0.75 1.26 0.34–4.71
32(7.2%) 0.79 0.94 0.56–1.57
5 (1.1%) 0.73 0.60 0.14–2.52
13 (2.8%) 1.0 0.99 0.46–2.19
10 (2.0%) 1.0 0.90 0.36–2.24
tion; other abbreviations as in Table 1.1
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Cilostazol and Ischemic Events After PCI January 18, 2011:280–9The tertile distribution of percentage inhibition (16%,
6% to 36%, 36%) at discharge was not associated with
therothrombotic complications (2.1% in the lowest vs.
.7% in the middle vs. 0.4% in the highest, p  0.133).
ROC curve analysis of PPR demonstrated that post-
reatment PRU measured at discharge was able to distin-
uish between patients with and without atherothrombotic
vents (area under the curve, 0.670, 95% confidence interval
CI]: 0.579 to 0.762, p  0.043) (Fig. 5). A PRU 252.5
as identified as the optimal cutoff value to predict post-
ischarge 6-month atherothrombotic events, providing a
ensitivity of 75%, specificity of 62%, positive predictive
alue (PPV) of 3.2%, and negative predictive value (NPV)
f 99.3%. Patients with PPR greater than the cutoff value
ad significantly higher rates of the primary end point
11.8% vs. 7.1%, p  0.030) and atherothrombotic compli-
ations (3.2% vs. 0.7%, p  0.014).
ultivariate analysis. Independent predictors of primary
utcome were lesion length (28 mm, hazard ratio [HR]:
.90, 95% CI: 1.05 to 3.43) and the PRU level at discharge
every increase in tertile, HR: 1.63, 95% CI: 1.12 to 2.37) in
he Cox regression analysis, which included age, sex, dia-
etes mellitus, hypertension, hypercholesterolemia, previous
I, clinical diagnosis, lesion length, reference vessel diam-
ter, multivessel intervention, type of DES, the use of
ilostazol, and PRU level at discharge. However, the use of
ilostazol was not an independent predictor of atherothrom-
otic events (HR: 0.88, 95% CI: 0.50 to 1.56) (Table 5).
Figure 5 ROC Curve for the VerifyNow P2Y12 Assay
The optimal cutoff for the atherothrombotic events (cardiac death, myocardial
infarction, and ischemic stroke) was a post-treatment platelet reactivity at dis-
charge 252.5 P2Y12 reaction units (area under the curve [AUC]: 0.670, 95%
confidence interval [CI]: 0.579 to 0.762, p  0.043). AUC  area under the
curve; ROC  receiver-operator characteristic.Figure 4 Differences in Cardiovascular Events
According to Tertile Distribution of PRU Value
(A) Composite major adverse cardiovascular outcomes (cardiac death, nonfatal
myocardial infarction [MI], ischemic stroke, and target lesion revascularization
[TLR]) showed a tendency for association with tertile distribution of PRU. (B)
Atherothrombotic events (cardiac death, nonfatal MI, and ischemic stroke)
were significantly associated with tertile distribution of PRU. (C) The rate of
TLR, however, was not associated with tertile distribution of PRU. Low indi-
cates PRU  0 to 164; Middle, PRU  165 to 264; and High, 265. Abbrevia-
tions as in Figure 2.
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January 18, 2011:280–9 Cilostazol and Ischemic Events After PCIdverse drug effects. At 6 months, there was no difference
n the use of nonstudy drugs except beta-blockers. Beta-
lockers were used more frequently in the TAT group (61%
s. 55%, p  0.048). Despite the more frequent use of
eta-blockers, TAT group showed a higher heart rate than
he DAT group at 6 months (TAT group, 73.3  12.0
eats/min vs. DAT group, 68.4  13.7 beats/min, p 
.001), which was more pronounced in females ( heart
ate, 2.4  14.5 beats/min in male, 6.6  14.1 beats/min in
emale, p 0.01) (Online Fig. 1). Cilostazol was stopped in
0 patients (6.6%) of the TAT group due to adverse
eactions, in contrast to 3 patients (0.7%) in the DAT
roup. Common side effects were palpitation (n  13,
.8%), headache (n  11, 2.4%), and gastrointestinal
rouble (n  3, 0.7%).
Bleeding complications did not differ between the 2
roups. The safety profiles are summarized in Table 6.
iscussion
espite the superiority of TAT to DAT in reducing PPR ex
ivo, this study suggests that TAT does not reduce the
dverse cardiovascular events after DES implantation. In
ddition, this study confirms that high residual platelet
eactivity assessed by the VerifyNow system is a predictor of
schemic events (8–10).
omparison of platelet inhibition between 2 antiplatelet
egimens. Cilostazol rapidly lowers PPR by increasing cyclic
denosine monophosphate levels by means of phosphodiester-
se III inhibition in platelets (18). We verified this effect both
t discharge and at 6 months after index PCI in this study.
The PRU level in the DAT group in this study was
igher than that of Caucasians in previous studies (7–9).
his finding is consistent with previous Korean results, and
t may be attributed to the high prevalence of CYP2C19
oss-of-function alleles that are associated with poor meta-
olic activation of clopidogrel in the Korean population,
eported to be 26.4% to 29.8% (*2) and 6.6% to 7.1% (*3) in
revious studies (28,29). Interestingly, the PRU level in the
AT group increased significantly at 6 months compared
ith that measured at discharge after the index procedure.
rug compliance was periodically checked, and there were
o differences between the 2 groups. Pharmacodynamic
achyphylaxis has been reported for aspirin (30,31). How-
ox Regression Analysis:redicto s of Composite Clinical OutcomesTable 5 Cox Regression Analysis:Predictors of Composite Clinical Outcomes
Risk Factor
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Lesion length 28 mm (vs. 28 mm) 1.75 (1.07–2.86) 2.10 (1.25–3.52)
High PRU level (every increase of tertile) 1.42 (1.04–1.93) 1.61 (1.16–2.25)
Use of cilostazol 0.91 (0.59–1.41) 0.90 (0.54–1.52)
Female 0.65 (0.39–1.10) 0.63 (0.34–1.17)
Multilesion PCI 1.80 (1.10–2.95) 1.57 (0.94–2.62)
MI  acute myocardial infarction; CI  confidence interval; HR  hazard ratio; PCI  percutane-
us coronary intervention; PRU  P2Y12 reaction unit.ver, this phenomenon and its underlying mechanism have
Dot been well evaluated in clopidogrel therapy. Further
tudies are needed to clarify this observation. Our results
uggest that the adjunctive use of cilostazol may overcome
his delayed hyporesponsiveness to clopidogrel, since the
AT group did not show this result.
omparison of clinical outcomes between the 2 anti-
latelet regimens. To date, CILON-T trial is the largest
rospective randomized study to assess efficacy of cilostazol
n clinical events. It did not show superiority of TAT to
AT with respect to ischemic clinical outcomes after DES
mplantation in a real-world setting. These results are
ontradictory to the results of previous smaller randomized
rial enrolling specific populations, such as diabetes and long
esions, which demonstrated that cilostazol is useful for
educing late luminal loss and thrombotic complications
fter DES implantation. There may be several possible
xplanations for this discrepancy.
First, the CILON-T trial had a different composition of
atients and primary end point from previous trials. This
rial enrolled all-comers who underwent DES implantation,
nd reflected real-world clinical settings, which included
bout 30% patients with diabetes mellitus and about 50%
hose with acute coronary syndrome. It was designed to
erify the superiority of TAT to DAT in the clinical
utcome after DES implantation. In contrast, in the
ECLARE-DIABETES and DECLARE-LONG stud-
es (15,16), investigators enrolled only high-risk subsets,
uch as diabetes mellitus or long lesions, and reported that
AT reduced angiographic late loss and the occurrence of
LR after DES implantation. Importantly, the primary end
oint of those studies was angiographic late loss, and they
ere not powered to show the clinical superiority of TAT to
AT. Another Chinese study reported that TAT reduced
ong-term cardiac and cerebral events after PCI in patients
ith acute coronary syndrome (26). However, the popula-
ion of this study did not include patients with DES only,
ut also included those with bare metal stents in about 50%.
Second, intensity of risk factor control in this study was
ifferent from previous ones. We prescribed statin to nearly
ll patients at discharge. At 6 months, mean low-density
ipoprotein cholesterol levels of both groups were about 60
g/dl (data not shown). Tight control of cholesterol can
educe platelet reactivity and neointimal hyperplasia in
afety Assessments in 2 GroupsTable 6 Safety Assessments in 2 Groups
Variable
TAT
(n  457)
DAT
(n  458) p Value
Bleeding complications 0.511
TIMI major 2 (0.4%) 1 (0.2%)
TIMI minor 1 (0.2%) 0 (0%)
Drug discontinuation 30 (6.6%) 3 (0.7%) 0.001
Heart rate, beats/min
Baseline 69.7 (11.9) 69.2 (12.7) 0.62
6 months 73.3 (12.0) 68.4 (13.7) 0.001ata are mean (SD) or n (%).
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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Cilostazol and Ischemic Events After PCI January 18, 2011:280–9atients with coronary heart disease (32,33), and thus might
ilute the potential benefit of cilostazol.
Third, we used zotarolimus-eluting and paclitaxel-eluting
tents in most of the patients, whereas previous trials exclu-
ively used sirolimus-eluting and paclitaxel-eluting stents
15,16). The effect of cilostazol on the angiographic outcome
f zotarolimus-eluting stents has not been reported.
Fourth, the TAT group showed significantly higher heart
ates at follow-up despite higher use of beta-blockers.
linical implication of positive chronotropic effect of
ilostazol has not been well assessed in the previous clinical
rials. Considering the high portion of patients with acute
oronary syndrome in this study, we cannot exclude the
ossibility that positive chronotropic effects of cilostazol
ay be associated with higher cardiovascular event rates,
eading to the negative result of this study. Interestingly,
ithin the female subgroup, TAT had significantly more
ardiovascular events than DAT, which may be partially
xplained by the finding that cilostazol induces a more
ronounced chronotropic effect in female patients. Further
tudies are warranted to confirm this finding. Although
ecent registry data suggested that the addition of cilostazol
n patients with acute MI is beneficial (34), it needs cautious
nterpretation considering the positive chronotropic effect of
ilostazol, especially in patients with significant left ventric-
lar dysfunction.
Finally, we cannot exclude selection bias of previous ran-
omized trials and confounders of previous registry studies. In
ddition, we cannot rule out publication bias which arises from
he tendency for researchers and editors to favor clinical results
hat are positive rather than negative or inconclusive.
mportance of platelet reactivity. In the Cox regression
nalysis, platelet reactivity measured at discharge was 1 of 2
ndependent predictors of composite cardiovascular events.
ertile distribution of PRU level rather than that of per-
entage inhibition was significantly associated with athero-
hrombotic events. ROC curve analysis of PPR demon-
trated that a PRU 252.5 was the optimal cutoff value to
redict post-discharge 6-month atherothrombotic events.
his is in line with previous studies (8–10) and adds new
vidence about the importance of PPR in Asians. The cutoff
evel was higher than in previous results, which were
eported to be 230 to 240 PRU (7–9). This may also be
ssociated with a high prevalence of loss-of-function alleles
f CYP2C19 in Koreans as previously described. If we
pplied 235 and 240 PRU, which were suggested as cutoff
evels in studies of Western countries, to our model,
ensitivity values were both 75%, but specificity values
ecreased to 54.5% and 57.0%. PPV decreased to 2%, and
PV was 99% in both cutoff levels.
Although the TAT group had a lower mean PRU level
han the DAT group as a whole, a significant number of
atients (30.4%, 108 of 355) in the TAT group still
elonged to the highest tertile level of PRU (264 PRU).
his suggests that many patients still have high PPR even
ith TAT. The presence of this subgroup, “hyporesponderso TAT,” may be an explanation of the finding that
nhanced platelet inhibition or lower mean PRU value as a
hole with TAT did not decrease the actual number of
linical events. These hyporesponders to TAT may be the
oughest group, one that has little additional benefit from
ilostazol therapy and also, the target population in need of
nother adjunctive or alternative pharmacologic interven-
ion. These findings suggest that not the antiplatelet regi-
en but the achievement of low PPR is important.
This study was not designed to evaluate the benefit of the
ersonalized antiplatelet therapy based on PPR, such as
ddition of cilostazol on top of DAT in patients showing
igh PPR. Ongoing studies that are designed to decide
ntiplatelet regimen based on the platelet function test may
how whether tailored therapy according to PPR can
mprove clinical outcomes in patients with PCI (35–37).
tudy limitations. First, despite its prospective and ran-
omized design, this study was open label. To compensate
or this limitation, the platelet function test was performed
n a blinded manner, and assessment of the clinical out-
omes was adjudicated by a separate board. Second, there
ight be a possible bias associated with clinical decisions
elated to TLR. Third, we measured platelet reactivity with
nly one method, the VerifyNow P2Y12 assay. Fourth, this
tudy was not powered to verify the effect of cilostazol on
ard end points, such as cardiac death and nonfatal MI.
ifth, bleeding end points were assessed by TIMI criteria,
uch as the occurrence of the composite of TIMI major or
IMI minor bleeding. We did not compare insignificant
leeding complications between the 2 groups. Thus, the rate
f bleeding complications was too low to analyze clinical or
aboratory predictors of hemorrhagic events.
onclusions
AT did not show superiority to DAT in reducing the
schemic events after DES implantation although it
chieved lower PPR. The PPR was more important in
redicting adverse clinical events after DES implantation
ather than the type of antiplatelet regimen. Further studies
re needed to warrant these findings.
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